十大外围投注平台app

Annual Report and Form 20-F
lol投注平台

01

lol投注平台

In 2018, we achieved a significant milestone by returning to 产品介绍 Sales growth. In 2019, we refreshed our strategy to focus on what comes next, and where we want our business to be in 2025. Our strategy reflects ideas which we crowdsourced from our employees and is underpinned by the initiatives outlined below which are intended to accelerate delivery of our strategy.


02

lol投注平台


In the first full year of our return to 产品介绍 Sales growth, we made good progress in line with our strategy. We anticipate 2020 to be another year of progress.

Leif Johansson, Chairman

AstraZeneca’s first full year of returning to 产品介绍 Sales growth was made possible by our ability to deliver our science to patients. We are now maximising and exploring the full potential of our leading medicines, rapidly advancing the next wave of science and positioning your Company for continued success.

Pascal Soriot, Chief Executive Officer

03

lol投注平台

2019 generated accelerating 产品介绍 Sales growth from outstanding New Medicine uptake, driving an increase to Core Operating profit.


十大外围投注平台app


Total Revenue*                                   
十大外围投注平台app

$24.4bn十大外围投注平台app


Net cash flow from operating activities
Up 13% at actual rate of exchange to $2,969 million                                   



十大外围投注平台app

$3.0bn十大外围投注平台app

// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.

*Total Revenue consists of Product Sales and Collaboration Revenue.

 

十大外围投注平台app


Reported operating profit
十大外围投注平台app


$2.9bn十大外围投注平台app


Core operating profit
十大外围投注平台app


$6.4bn十大外围投注平台app

十大外围投注平台app


Reported EPS
十大外围投注平台app


$1.03十大外围投注平台app


Core EPS
十大外围投注平台app


$3.50十大外围投注平台app



04

lol投注平台

We are a global, science-led, patient-focused, pharmaceutical company. We have transformed our pipeline and returned to growth. As a result of continued pipeline delivery and commercial execution, we are now entering a new stage in our journey.


lol投注平台


Total Product Sales

$23,565m十大外围投注平台app

2018: $21,049m
2017: $20,152m

 

lol投注平台

lol投注平台


lol投注平台


十大外围投注平台app

十大外围投注平台app

十大外围投注平台app

十大外围投注平台app

十大外围投注平台app

十大外围投注平台app

十大外围投注平台app

十大外围投注平台app



lol投注平台


Dividends
lol投注平台

$3,592m十大外围投注平台app

2018: $3,484m
2017: $3,519m
十大外围投注平台app


Proceeds from issue of shares1lol投注平台

$(3,525)m十大外围投注平台app

2018: $(34)m
2017: $(43)m
十大外围投注平台app


Total
lol投注平台

$67m十大外围投注平台app

2018: $3,450m
2017: $3,476m

十大外围投注平台app


 1. In April 2019, the Company completed a placing of 44,386,214 new Ordinary Shares of $0.25 each in the Company.


lol投注平台

05

lol投注平台

At AstraZeneca, health is our business and our contribution to society. How we operate supports sustainable ecosystems for healthcare that benefit people and our planet through science-based innovation.

Our aspiration is for the future to be healthy and that we are an active participant for a healthy society, planet and business. Our pioneering medicines touch the lives of millions of people so it is a business imperative that we are partners and activists for solutions to global health. At the heart of our sustainability approach is access to healthcare and its connection to environmental protection, and ethics and transparency.



More information


More information


More information